Evaluation of second-line treatment options in non-small cell lung cancer - Introduction

被引：1
作者：
Scagliotti, GV [1 ]
机构：
[1] Univ Turin, Dept Clin & Biol Sci, Turin, Italy
来源：
SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 01期
关键词：
D O I：
10.1053/j.seminoncol.2005.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1 / S2
页数：2
相关论文
共 50 条
[41]   From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? [J].
D'Argento, Ettore ;
Rossi, Sabrina ;
Schinzari, Giovanni ;
Strippoli, Antonia ;
Basso, Michele ;
Cassano, Alessandra ;
Barone, Carlo .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
[42]   A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer [J].
Holmes, J ;
Dunlop, D ;
Hemmett, L ;
Sharplin, P ;
Bose, U .
PHARMACOECONOMICS, 2004, 22 (09) :581-589
[43]   A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer [J].
Jeremy Holmes ;
David Dunlop ;
Lindsay Hemmett ;
Peter Sharplin ;
Uday Bose .
PharmacoEconomics, 2004, 22 :581-589
[44]   Histologic review of second-line permetrexed treatment in patients with non-small cell lung cancer (NSCLC) [J].
Virani, S. ;
Almubarak, M. ;
Rogers, J. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[45]   Experience with osimertinib in second-line treatment of non-small cell lung cancer at Nottingham University Hospitals [J].
Sadiq, M. ;
Khan, S. ;
Lopez-Escola, C. ;
Arora, A. ;
Hennig, I. ;
Abdallah, S. ;
Soomro, I. .
LUNG CANCER, 2020, 139 :S62-S62
[46]   Pemetrexed vs docetaxel cost analysis in second-line non-small cell lung cancer treatment [J].
Ravasio, Roberto .
FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (02) :119-126
[47]   Second and third line treatment in non-small cell lung cancer [J].
Favaretto, Adolfo ;
Pasello, Giulia ;
Magro, Cristina ;
Schettino, Clorinda ;
Gridelli, Cesare .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (02) :117-126
[48]   Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow? [J].
Greillier, L. ;
Barlesi, F. .
REVUE DES MALADIES RESPIRATOIRES, 2012, 29 (01) :4-6
[49]   Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer [J].
Georgoulias, VA .
LUNG CANCER, 2002, 38 :S61-S66
[50]   First- and second-line biomarker utilization in non-small cell lung cancer [J].
Leong, Matthew ;
Azimpouran, Mahzad ;
McCloskey, Audrey ;
Sankar, Kamya ;
Vail, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345